Evaluation of survival and recurrence patterns in esophageal cancer patients with pathological response to neoadjuvant chemoradiotherapy

对接受新辅助放化疗后病理反应的食管癌患者的生存和复发模式进行评估

阅读:1

Abstract

INTRODUCTION: There have been a limited number of studies conducted to determine the pattern of relapse and survival in patients after neoadjuvant chemoradiotherapy and surgery for esophageal cancer. AIM: To evaluate the survival and recurrence patterns in esophageal cancer patients with a pathologic response to neoadjuvant chemoradiotherapy. MATERIAL AND METHODS: This retrospective study was performed on 159 esophageal cancer patients receiving neoadjuvant chemoradiotherapy. A checklist of demographic and clinicopathological variables was filled. Then, survival and recurrence patterns in esophageal cancer patients with complete and near complete pathologic responses to neoadjuvant chemoradiotherapy were evaluated. RESULTS: Among 159 of 1117 patients who met the inclusion criteria, 147 patients had a complete pathological response and 12 had a near complete pathological response. In this study variables included age, type of tumor and tumor distance from the incisors, which showed no significant difference, and among them, only sex and addiction were associated with the results. The overall survival and 1 year and 3 years disease-free survival were 59.1 ±2.5%, 89.4 ±2.7%, 62.8 ±5.7% respectively. CONCLUSIONS: Almost all patients with complete pathological responses had well-differentiated cells and those with near complete responses had moderately differentiated cells; the most common type of recurrence was observed in the systemic type of disease and the most common sites were the lungs and liver. Women and people with no history of addiction showed better responses to treatment and had higher levels of survival.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。